Daiichi Pharmaceutical, GE Healthcare to Collaborate in R&D for Contrast Media.Tokyo, Japan, Sept 13, 2005 - (JCNN JCNN Japan Corporate News Network ) - Daiichi Pharmaceutical announced on September 12 that it has signed a research and development agreement with GE Healthcare GE Healthcare is a $18 billion (USD) unit of General Electric (GE). It employs more than 46,000 people worldwide and is headquartered in Chalfont St. Giles, Buckinghamshire, United Kingdom. GE Healthcare is the first GE business segment headquartered outside the United States. . From now on, the two companies will strive to develop innovative contrast media (excluding ones for radioisotope radioisotope: see radioactive isotope. Radioisotope (biology) A radioactive isotope used in studying living systems, such as in the investigation of metabolic processes. diagnosis) that can address the needs of patients in Japan. Since 1987, the two companies have joined hands in the field of contrast media, which have led Daiichi Pharmaceutical to distribute several contrast media provided by GE Healthcare including Omniscan in Japan. Further, the two partners have co-developed Sonazoid, a contrast medium for ultrasonic diagnosis that received approval in May 2004. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion